Evotec has agreed to discover and develop small molecules for Novartis, in a deal that includes milestone payments of US$28 M. Although the two companies have been collaborating on various agreements since the late nineties, this latest agreement is potentially the most significant, which allows Evotec to discover and develop drug candidates for Novartis through to clinical trials.